%0 Journal Article
%T Plasma VEGF-A Short Isoforms as a Predictive Biomarker for Bevacizumab Efficacy in First-Line Treatment of Metastatic Colorectal Cancer: A Phase II Study (WJOG7612GTR)
%A Siti Farhana Ismail
%A Nur Amalina Hassan
%A Mohd Hafiz Musa
%J Archive of International Journal of Cancer and Allied Science
%@ 3108-4834
%D 2025
%V 5
%N 1
%R 10.51847/PcIAGZ3VSM
%P 125-137
%X This prospective study was designed to determine whether plasma vascular endothelial growth factor-A short isoforms (pVEGF-Asi) could predict responsiveness to bevacizumab (BV) and to investigate additional circulating biomarkers in metastatic colorectal cancer (mCRC) patients receiving modified FOLFOX6/XELOX in combination with BV (mFOLFOX6/XELOX + BV). Plasma samples obtained before treatment initiation were collected from 100 mCRC patients treated with first-line mFOLFOX6/XELOX + BV. Levels of 11 angiogenesis-related circulating proteins, including pVEGF-Asi, together with 22 cancer-related gene mutations identified in circulating tumor DNA, were evaluated. For the primary endpoint, the hazard ratio (HR) for progression-free survival (PFS), estimated using a Cox proportional hazards model, was prespecified to be 
%U https://smerpub.com/article/plasma-vegf-a-short-isoforms-as-a-predictive-biomarker-for-bevacizumab-efficacy-in-first-line-treatm-ci2onpop5xsiok7